Highlights,Bristol Myers Squibb's shares rose following the FDA's approval of COBENFY, the first new schizophrenia treatment ...

Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...

Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure, the personal consumption expenditures ...

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...

The U. S. Food and Drug Administration (FDA) has signed off on Cobenfy, the first revolutionary treatment for schizophrenia ...

U.S. equities were mixed at midday as the Federal Reserve's favored measure of inflation was lower than anticipated.

Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.

Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma ...

Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of ...

The Dow jumped more than 400 points Friday to an all-time high after a benign inflation report cleared the way for the ...